Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZL 1102

Next Previous
Drug Profile

ZL 1102

Alternative Names: Antibody VH domain therapeutic - Zai lab; CB-001 - Crescendo Biologics; IL-17 Humabody®; ZL-1102

Latest Information Update: 20 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crescendo Biologics
  • Developer ZAI Lab
  • Class Anti-inflammatories; Antibodies; Antipsoriatics; Immunoglobulin fragments; Immunotherapies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 08 May 2025 Zai labs terminates a phase-II clinical trials in Plaque psoriasis (In the elderly, In adults) in Australia (Topical) (NCT06380907)
  • 23 May 2024 Phase-II clinical trials in Plaque psoriasis (In the elderly, In adults) in Australia (Topical)
  • 08 May 2024 Zai lab plans to initiate a global phase II trial for Plaque psoriasis in the second half of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top